Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 1/20 | 0.49 |
| ▸ | CMA1 | P23946 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.43 |
| ▸ | PKM | P14618 | 2/20 | 0.43 |
| ▸ | GAA | P10253 | 2/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | FAAH | O00519 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.39 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.39 |
| ▸ | PDE5A | O76074 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31066579 | 0.77 | CYP2D6 (0.58) | CYP2D6CMA1SMN1; SMN2PKMGAA | |
| SCHEMBL3860303 | 0.74 | CYP2D6 (0.40) | CYP2D6CMA1SMN1; SMN2PKMGAA | |
| SCHEMBL32665579 | 0.71 | BRD4 (0.40) | SMN1; SMN2GAATSHRKMT2AALDH1A1 | |
| SCHEMBL17420665 | 0.71 | BRD4 (0.53) | CMA1SMN1; SMN2GAAALDH1A1 | |
| SCHEMBL20504054 | 0.70 | MAPK1 (0.44) | CYP2D6CMA1SMN1; SMN2PKMGAA | |
| SCHEMBL1895931 | 0.69 | ALDH1A1 (0.46) | CYP2D6CMA1SMN1; SMN2KDM4ETSHR | |
| SCHEMBL3143023 | 0.69 | CYP2D6 (0.68) | CYP2D6SMN1; SMN2PKMGAAKDM4E | |
| SCHEMBL16883442 | 0.68 | CYP2D6 (0.71) | CYP2D6SMN1; SMN2PKMGAAKDM4E | |
| SCHEMBL13574529 | 0.68 | CYP2D6 (0.71) | CYP2D6SMN1; SMN2PKMGAAKDM4E | |
| SCHEMBL32665634 | 0.68 | CMA1 (0.51) | CMA1SMN1; SMN2KDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8314087-B2 | Nitrogen-containing heterocyclyl ketones and methods of use | AMGEN INC. (US) | 2012-11-20 | — | — | US | disclosed |
| EP-2114898-A2 | NITROGEN-CONTAINING HETEROCYCLYL KETONES AND THEIR USE AS C-MET INHIBITORS | Amgen Inc. (US) | 2009-11-11 | — | — | EP | disclosed |
| US-20080280917-A1 | Nitrogen-Containing heterocyclyl ketones and methods of use | AMGEN INC. (US) | 2008-11-13 | — | — | US | disclosed |
| WO-2008103277-A2 | NITROGEN-CONTAINING HETEROCYCLYL KETONES AND THEIR USE AS C-MET INHIBITORS | AMGEN INC. (US) | 2008-08-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080280917-A1 | Nitrogen-Containing heterocyclyl ketones and methods of use | HGF, HGFAC, MET | CYP2D6 519/4885CMA1 1342/4885SMN1; SMN2 864/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.